新型全基因组显著基因位点与年龄相关性黄斑变性继发地图样萎缩病灶生长的评估
这项汇总分析合并了4项独立研究,纳入935例年龄相关性黄斑变性继发地图样萎缩患者,评估遗传变异与病灶生长速度的关联。研究发现两个具有保守全基因组显著性的基因位点,每个次要等位基因平均使地图样萎缩生长速度增加约15%或每年0.05 mm,并提示PRMT6和LSS为最可能的进展相关基因。
要点
- 共识别出2个与地图样萎缩病灶生长相关的全基因组显著基因位点,每个次要等位基因平均使生长速度增加约15%或每年0.05 mm。
- PRMT6(1号染色体;斜率0.046,95%CI 0.026-0.066;P=4.09×10⁻⁸)与LSS(21号染色体;斜率0.105,95%CI 0.068-0.143;P=4.07×10⁻⁷)为最可能的进展相关基因。
- PRMT6和LSS是未来研究地图样萎缩进展功能方面及设计新型靶向治疗方案的候选基因。
核心结论
- 这些数据进一步揭示地图样萎缩病灶生长的遗传结构,PRMT6和LSS是未来研究地图样萎缩进展功能方面及设计新型靶向治疗方案的候选基因。
研究设计与样本
- 本汇总分析合并4项独立研究:FAM研究、DSGA研究、AREDS和GATE研究,共纳入935例年龄相关性黄斑变性继发地图样萎缩患者(平均[SD]年龄74.7[7.8]岁;547例女性[59.0%])。
主要发现
- 共识别出2个具有保守全基因组显著性的基因位点,每个全基因组关联变异的次要等位基因平均使地图样萎缩生长速度增加约15%或每年0.05 mm。
- 基因 prioritized 分析提示PRMT6(1号染色体;斜率0.046,95%CI 0.026-0.066;P=4.09×10⁻⁸)和LSS(21号染色体;斜率0.105,95%CI 0.068-0.143;P=4.07×10⁻⁷)为最可能的进展相关基因。
关键数值与推荐
- 对经平方根转换的地图样萎缩生长速度与通过质量控制的7,596,219个遗传变异之间的相关性采用线性回归估计,并校正双侧地图样萎缩存在、病灶斑点数量及随访时间等已知影响因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Age-related macular degeneration (AMD) is a common threat to vision loss in individuals older than 50 years. While neovascular complications in AMD are treatable, there is currently no therapy for geographic atrophy secondary to AMD. Geographic atrophy lesion progression over time shows considerable interindividual variability, but little is known about prognostic factors. OBJECTIVE: To elucidate the contribution of common genetic variants to geographic atrophy lesion growth. DESIGN, SETTING, AND PARTICIPANTS: This pooled analysis combined 4 independent studies: the Fundus Autofluorescence Imaging in Age-Related Macular Degeneration (FAM) study, the Directional Spread in Geographic Atrophy (DSGA) study, the Age-Related Eye Disease Study (AREDS), and the Geographic Atrophy Treatment Evaluation (GATE) study. Each provided data for geographic atrophy lesion growth in specific designs. Patients with geographic atrophy secondary to AMD were recruited to these studies. Genotypes were retrieved through the database of Genotypes and Phenotypes (for AREDS) or generated at the Cologne Center for Genomics (for FAM, DSGA, and GATE). MAIN OUTCOMES: The correlation between square root-transformed geographic atrophy growth rate and 7 596 219 genetic variants passing quality control was estimated using linear regression. The calculations were adjusted for known factors influencing geographic atrophy growth, such as the presence of bilateral geographic atrophy as well as the number of lesion spots and follow-up times. MAIN OUTCOMES AND MEASURES: Slopes per allele, 95% CIs, and P values of genetic variants correlated with geographic atrophy lesion growth. RESULTS: A total of 935 patients (mean [SD] age, 74.7 [7.8] years; 547 female participants [59.0%]) were included. Two gene loci with conservative genome-wide significance were identified. Each minor allele of the genome-wide associated variants increased the geographic atrophy growth rate by a mean of about 15% or 0.05 mm per year. Gene prioritization within each locus suggests the protein arginine methyltransferase 6 gene (PRMT6; chromosome 1; slope, 0.046 [95% CI, 0.026-0.066]; P = 4.09 × 10-8) and the lanosterol synthase gene (LSS; chromosome 21; slope, 0.105 [95% CI, 0.068-0.143]; P = 4.07 × 10-7) as the most likely progression-associated genes. CONCLUSIONS AND RELEVANCE: These data provide further insight into the genetic architecture of geographic atrophy lesion growth. Geographic atrophy is a clinical outcome with a high medical need for effective therapy. The genes PRMT6 and LSS are promising candidates for future studies aimed at understanding functional aspects of geographic atrophy progression and also for designing novel and targeted treatment options.
引用
- Grassmann F, Harsch S, Brandl C, et al. Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular Degeneration. JAMA Ophthalmol. 2019. PMID: 31120506. doi:10.1001/jamaophthalmol.2019.1318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。